Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033

NCT ID: NCT07097948

Last Updated: 2025-08-01

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-31
• Study Completion Date: 2030-07-31

Brief Summary

Small cell lung cancer (SCLC) is highly malignant and aggressive, with most patients presenting with metastases at diagnosis. For postoperatively incidentally detected SCLC (identified unexpectedly in pathological examinations after surgery), conventional adjuvant chemoradiotherapy has shown limited efficacy, characterized by high recurrence rates and suboptimal long-term survival.Notably, advances in immunotherapy have transformed SCLC management. The EXTENTORCH trial, a pivotal study published in JAMA Oncology, demonstrated that toripalimab plus chemotherapy significantly improved outcomes in extensive-stage SCLC (ES-SCLC), achieving a reduced risk of progression or death (HR=0.67, 95% CI 0.54-0.82, P<0.001) with manageable safety, marking a substantial therapeutic breakthrough. Given the proven efficacy of toripalimab in ES-SCLC, there is a strong rationale to extend this strategy to postoperatively incidentally detected SCLC. This trial aims to evaluate the efficacy and safety of toripalimab as adjuvant maintenance therapy in this cohort, with the objective of reducing recurrence and enhancing long-term survival.

Conditions

Postoperative Incidental Small Cell Lung Cancer; Toripalimab Adjuvant Therapy Evaluation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Postoperative Adjuvant Chemotherapy

In this arm, enrolled subjects will receive postoperative adjuvant chemotherapy, totaling 4 cycles, with each cycle lasting 3 weeks.

Group Type: ACTIVE_COMPARATOR

Etoposide

Intervention Type: DRUG

Specified dose on specified days.

Platinum

Intervention Type: DRUG

Specified dose on specified days.

Postoperative Chemotherapy Combined with Toripalimab Maintenance

In this arm, enrolled subjects will first receive postoperative chemotherapy (4 cycles, 3 weeks per cycle), followed by toripalimab for immunological maintenance therapy, administered once every 3 weeks.

Group Type: EXPERIMENTAL

Etoposide

Intervention Type: DRUG

Specified dose on specified days.

Platinum

Intervention Type: DRUG

Specified dose on specified days.

Toripalimab

Intervention Type: DRUG

Specified dose on specified days.

Interventions

Etoposide

Specified dose on specified days.

Intervention Type: DRUG

Platinum

Specified dose on specified days.

Intervention Type: DRUG

Toripalimab

Specified dose on specified days.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. The patient shall sign the Informed Consent Form;

2. Aged ≥ 18 years;

3. Patients with definitely incidental SCLC confirmed by pathological results after radical resection of lung cancer;

4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;

5. Life expectancy is at least 12 weeks;

6. Good function of other major organs (liver, kidney, hematological system, etc.);

7. Fertile female patients must undergo a pregnancy test within 7 days before the start of treatment with a negative result; and reliable contraceptive measures (such as intrauterine devices, contraceptives and condoms) should be used during the trial and within 30 days after its completion;

8. Fertile male subjects must use condoms for contraception during the trial and within 30 days after its completion.

Exclusion Criteria

1. Patients with a malignancy other than SCLC within five years prior to the start of this trial;

2. Participants with any unstable systemic disease (including uncontrolled hypertension, severe arrhythmia, etc.);

3. With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment;

4. Participants who are allergic to the test drug or any auxiliary materials;

5. Participants with active hepatitis B, hepatitis C or HIV;

6. Participants with Interstitial lung disease currently;

7. Pregnant or lactating women;

8. Any malabsorption;

9. Participants suffering from nervous system diseases or mental diseases that cannot cooperate;

10. Other factors that researchers think it is not suitable for enrollment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

Sponsor Role: lead

Responsible Party

Peng Zhang

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Shanghai Pulmonary Hospital

Shanghai, China, China

Countries

China

Central Contacts

Peng Zhang, PhD

Role: CONTACT

zhangpeng1121@tongji.edu.cn

02165115006

Facility Contacts

Peng Zhang, PhD

Role: primary

zhangpeng1121@tongji.edu.cn

02165115006

Other Identifiers

LungMate-033

Identifier Type: -

Identifier Source: org_study_id